Clinics in Laboratory Medicine 2005: Vol 25 Index

2005·4 MB·English

CLINICS IN
A
LABORATORY
ESALUSNEDVEIRESR MEDICINE
Clin Lab Med 25 (2005) 851-875
Cumulative Index 2005
Note: Page numbers of article titles are in boldface type.
A pancreas-specific markers
Accreditation Council for Graduate in, 29-31
Medical Education program, fine phospholipase A-2 in, 31
needle aspiration requirements of, treatment of, 20
639
Acute Physiology and Chronic Health
Acinar cells, calcium disturbances in, in Evaluation (APACHE) II criteria, in
pancreatitis, 2-4 acute pancreatitis, 20, 22-23
Acquired immunodeficiency syndrome. Adenofibroma, metanephric, 388-390
See Human immunodeficiency virus Adenoid cystic carcinoma, of breast,
infection. cytomorphology of, 764-766
Acromegaly, colorectal cancer in, 147 Adenoma(s)
Acute lymphoblastic leukemia, stem cell breast
transplantation for, 528-531 lactating, cytomorphology of,
693
Acute myeloid leukemia, stem cell tubular, cytomorphology of,
transplantation for, 522—524 693, 698
Acute pancreatitis, 17-37 renal
clinical course of, 17 classification of, 233, 235-239
definition of, 20 metanephric, 292, 379-384
genetic factors in, 31-32 papillary, 284, 286
mortality in, 17, 20, 23-24 Adenomyoepithelioma, of breast,
multi-system organ failure in, 19-20 cytomorphology of, 698-701
necrosis in, 19, 23-24
pathogenesis of, 1-15 Adenosis tumor, of breast,
calcium signaling disturbances in, cytomorphology of, 698
2-4 microglandular, 694
cathepsin B in, 7—9 sclerosing, 694
trypsin in, 9-11 Adrenal glands, renal cell carcinoma
zymogen activation in, 5-9 spread to, 444
pathophysiology of, 18-19
severity of Adrenal rests, 232-233
defining, 20
Adult respiratory distress syndrome, in
predictors of, 20
acute pancreatitis, 19
clinical assessment in, 23
computed tomography in, AE1/AE3, in renal cell carcinoma, 249,
24-25 251
genetics, 31—32
AIDS. See Human immunodeficiency
inflammation markers in,
Virus infection.
25-29
laboratory tests in, 23-24 Air drying, of breast cytology specimens,
marker combinations in, 31 640-643
multi-factorial scoring
systems for, 21-23 Albarran and Imbert renal tumor
observations in, 23 classification, 234
0272-2712/05/$ - see front matter © 2005 Elsevier Inc. All rights reserved.
doi:10.1016/S0272-2712(05)00106-X labmed.theclinics.com
852 CUMULATIVE INDEX
Alcoholic pancreatitis Aortic grafts. See Cardiovascular tissue
CFTR gene mutations in, 92-93 grafts.
pancreatic secretory trypsin inhibitor
APACHE (Acute Physiology and Chronic
Kazal type in, 67-68
Health Evaluation) II criteria,
Algorithms, prognostic, for renal cell in acute pancreatitis, 20, 22-23
carcinoma surgical treatment, 452-456
APC gene mutations
ALL (acute lymphoblastic leukemia), stem in colorectal cancer, 137, 139-140,
cell transplantation for, 528-531 142
in gastric cancer, 209
Alloderm, for skin coverage, 592
pancreatic carcinoma risk in, 121
Alpha-TFEB gene fusion, in renal
Aphidicolin-inducible fragile site,
carcinoma, 370-375
mutations at, in papillary renal cell
Alveolar soft part sarcoma, renal, 363-367, carcinoma, 285
369-370 Aplastic anemia, stem cell transplantation
American Association of Blood Banks for, 524-526
accreditation by, 488, 490, 492-493
Apocrine carcinoma, of breast,
standards of, 488, 490, 492-493
cytomorphology of, 766-767
American Association of Tissue Banks Apoptosis, in Helicobacter pylori
accreditation by, 488, 490-493
infections, 203-204
Skin Council of, 595-596
standards of, 488, 490-493, 512-513 Aspirin, for colorectal cancer prevention,
158-159
American College of Radiology Breast
Imaging Reporting and Data System ASPL-TFE3 gene fusion, in renal
(BIRADS), 674-676, 733-734 carcinoma, 364-366, 369-370
American Society of Cytology Assisted reproduction technologies, cells
cytologic grading recommendations and tissues for. See Reproductive
of, 747-749 cell and tissue banking.
fine needle aspiration requirements of,
Ataxia-telangiectasia, pancreatic
639-640
carcinoma risk in, 122
report terminology recommendations
of, 753, 756 Atlanta International Symposium on
Acute Pancreatitis, acute pancreatitis
AML (acute myeloid leukemia), stem cell
classification of, 20
transplantation for, 522—524
ATM gene mutations, pancreatic
Amsterdam criteria, for hereditary
carcinoma risk in, 122
nonpolyposis colorectal cancer,
i87-189 Atrophy, gastric, in Helicobacter pylori
infections, 200-201
Amylase, in pancreatitis, 29
Atypical hyperplasia, of breast,
Anaplasia, in nephroblastoma, 348-350
cytomorphology of, 718-724,
Anemia 830-832
aplastic, stem cell transplantation for,
Autodigestion, in pancreatitis, 18-19
524-526
protection against, 63-64
in colorectal cancer, 148
Autologous tissue donation, retrieval of,
Angiomyolipoma, epithelioid, renal, 331,
405-408 480
Azathioprine, for skin graft rejection, 594
Anisonucleosis, in breast cancer, 734, 736
Anterior lamellar keratoplasty, 611-613 B
Antibiotics, for cardiovascular tissue B lymphocytes, depletion of, for islet cell
disinfection, 576-577 transplantation, 550-551
Antimitochondrial antibody stain, for B72.3 monoclonal antibody, in atypical
oncocytoma, 320 breast hyperplasia, 723
CUMULATIVE INDEX 853
Barium enema, in colorectal cancer, 51 combination cortical and cancellous,
Bcl-2 protein, in oncocytoma, 320 500
complaints about, 514
Beckwith-Wiedemann syndrome, cortical, 500, 505
nephroblastoma in, 343, 346 demineralized, 501-502, 505
distribution of, 514
Bell, Elexious Thompson, renal tumor documentation of, 514
classification of, 235—236 freeze drying of, 512-513
Beta cell transplantation. See Islet cell goals of, 500—S01
replacement therapy. HIV transmission in, 487
immunology of, 475, 502-503
Bethesda criteria, for hereditary incoming, inspection of, 513-514
nonpolyposis colorectal cancer, incorporation of, 499-501
187-189 indications for, 483, 504—S05
BHD gene mutations, 270 mechanical properties of, 511-512
osteoarticular, 503, 507
Binney renal tumor classification, 233 osteoconduction in, 500
packaging of, 509
Biomechanical properties, of bone and soft
physical modification of, 501
tissue grafts, 511-512
processing of, 504-505, 508-512
Biopsy rehydration of, 513
of breast soft tissue grafts combined with, 507
core needle, 635-637, 658-663, specialty, 505-506
679-688 sterilization of, 510-511
fine needle aspiration. See storage of, 512-513
Breast lesions, fine needle tissue engineering for, 501
aspiration biopsy in. types of, 504
of colon polyps, 160
Bone marrow transplantation. See Stem
BIRADS (American College of Radiology cell transplantation.
Breast Imaging Reporting and Data
System), 674-676, 733-734 Bone morphogenic proteins, in bone
grafts, 501-502
Birt-Hogg-Dubeé syndrome, renal
Bone-patellar tendon-bone grafts, 507
neoplasms in, 269-270, 328-329
oncocytosis, 326 Botryoid nephroblastoma, 367
renai cell carcinoma, 269-270
BRCA gene mutations, pancreatic
Black’s nuclear grading scheme, for breast carcinoma risk in, 121-122, 124-126
carcinomas, 748-749, 811-812
Breast cancer
Bleeding carcinoma with choriocarcinomatous
in colon polyps, 148 features, cytomorphology of,
in colorectal cancer, 145, 148, 771-772
150-151 core needle biopsy in
Blood, testing of, in tissue donor, 478 costs of, 658
versus fine needle aspiration
Bloom syndrome, nephroblastoma in, 343, biopsy, 635-637, 658-663,
346 679-688
cytomorphology of, 733-760, 761-775
Bone grafts, 499-518
accuracy of, 750-752
allograft, versus autologous, 499
adenoid cystic carcinoma,
alternatives to, 515
764-766
autologous
apocrine carcinoma, 766-767
incorporation of, 500
carcinoma with
versus allograft, 499
choriocarcinomatous
bone morphogenetic proteins and,
features, 771-772
501-502 diagnostic criteria for, 734-735
cancellous, 500, 505
ductal carcinoma and ductal
clostridial infection transmission in,
carcinoma in situ,
489
735-738, 754-755
854 CUMULATIVE INDEX
Breast cancer (continued ) costs of, 658
ductal lavage for, 833-839 versus fine needle aspiration
ductoscopy for, 792, 845-850 biopsy, 635-637, 658-663,
false diagnosis in, 751-752, 679-688
754-755 cytomorphology of
fine needle aspiration biopsy in. benign, 689-712
See Breast lesions, fine directed vacuum-assisted biopsy
needle aspiration biopsy in. in, 659-667
for grading, 747-749 ductoscopy in, 792, 845-850
lipid-rich carcinoma, 769-771 fine needle aspiration biopsy in.
lobular carcinoma and lobular See Breast lesions, fine
carcinoma in situ, 736, needle aspiration biopsy in.
739-740, 754-755 in cancer, 733-760, 761-775
medullary carcinoma, 736, in fibrocystic change, 713-731
746-747 in high-risk proliferative disease,
metaplastic carcinoma, 762-764 713-731
mucinous (colloid) carcinoma, in premalignant disease,
736, 745, 789 713-731
nipple fluid, 787-794 in proliferative disease. 694-696
papillary carcinoma, 736, intraoperative imprint cytology
742-745 in, 795-807
report terminology for, 753-756 nipple fluid for, 787-794
secretory carcinoma, 767-769 diagnostic terminology of, 644-646
squamous cel! carcinoma, ductal lavage in, 833-839
761-762 ductoscopy in, 792, 845-850
tubular carcinoma, 736, fine needle aspiration biopsy in,
741-742 631-654
within triple test context, ancillary studies in, 646-649
733-734 “blind” (in clinically normal
familial, pancreatic carcinoma risk in, tissue), 634, 647-648
121-122 credentialing for, 638-640
intraoperative imprint cytology in, diagnostic terminology in,
795-807 644-646
prognostic factors in, 809-825 | for prognosis, 809-825, 829-833
DNA ploidy, 814-816 image-directed, 655-678
HER-2/neu oncogene, 816-818 assessment categories in,
hormone receptors, 812-814 674-676
lymph node status, 810 cyst aspiration, 670-672
nuclear grade, 811-812 cytologic interpretation in,
p53 tumor suppressor, 818-819 674
tumor size, 810-811 cytology limitations in,
tumor type, 811 657-659
equipment for, 656-657
Breast lesions
magnetic resonance
benign, cytomorphology of, 689-712
imaging, 667-668
epithelial, 696-698
solid masses, 672-674
fibroepithelial, 700-701
stereotactic, 636-637,
in males, 696, 754-755
664-667
inflammatory, 689-691
ultrasound, 637, 663-664,
lymphohistiocytic, 705-706
667-670
mesenchymal, 701-705
versus core needle biopsy,
myoepithelial, 698-700
658-663
pregnancy-related changes,
in benign disease, 689-712
692-693, 754-755
in common malignant tumors,
proliferative, 694-696 733-760
treatment-induced changes,
in fibrocystic change, 713-731
691-692
in high-risk proliferative disease,
common malignant, cytomorphology 713-731
of, 733-760
in premalignant disease, 713-731
core needle biopsy in
CUMULATIVE INDEX an
in rare malignant tumors, Cancer
761-775 breast. See Breast cancer.
indications for, 633-637 colorectal. See Colorectal cancer.
medical-legal issues in, 777-785 gastric. See Gastric cancer.
post-biopsy recommendations in, ovarian, familial, pancreatic
650-651 carcinoma risk in, 121—122
practice guidelines for, 631-633 pancreatic. See Pancreas, cancer of.
rrevailing recommendations
versus contemporary Candidiasis, transmission of, in tissue
practices in, 631-654 grafts, 488
random periareolar, 648 Carboxypeptidase, early activation of, in
technique for, 640-644 pancreatitis, 5-9
training for, 638-640
versus core needle biopsy, Carboxypeptidase B activation protein, in
635-637, 658-663, 679-688 pancreatitis, 30
intraoperative imprint cytology in, Carcinoembryonic antigen, in colorectal
795-807 cancer, 148-149
malignant. See Breast cancer.
nipple fluid cytology in, 787-794 Carcinoma ?
nonpalpable, 655-678 adenoid cystic, of breast, 764-766
core needle biopsy in, 658-663, apocrine, of breast, 766-767
682-683 collecting duct. See Collecting duct
fine needle aspiration biopsy in, carcinoma.
656-659, 682 cystic, of breast, 752
recommendations for, ductal, 735-738, 754-755
versus contemporary lipid-rich, of breast, 769 77)
practices, 631-654 lobular, of breast, 736, 739-740,
image-guided biopsy of 754-755
BIRADS criteria for, medullary, of breast, 736, 746-747
674-676 metaplastic, of breast, 762-764
cyst aspiration, 670-672 mucinous, tubular, and spindle cell,
cytologic interpretation in, 393-398
674 mucinous (colloid), of breast. 736,
magnetic resonance imaging 745, 789
in, 667-668 pancreatic. See Pancreas, cancer of.
solid mass, 672-674 papillary, of breast, 736, 742-745
stereotactic, 664-667 renal cell. See Renal cell
ultrasound, 663-664. carcinoma(s).
668-670 sarcomatoid carcinoma, renal,
rare malignant, cytomorphology of, 291-292, 419, 440-441
761-775 secretory, of breast, 767-769
squamous cell, of breast, 761-762
c tubular, of breast, 736, 741-742
with choriocarcinomatous features,
Cadherins, in Helicobacter pylori infections, of breast, 771-772
203 Cardiovascular tissue grafts, 571-585
CagA, of Helicobacter pylori, gastric cancer autologous, 579-580
and, 200, 203 cellular, 580-581
disease transmission in, 488, 575
Calcific pancreatitis, tropical, 55, 66-67 donor criteria for, 572-574
Calcium phosphate, as bone graft durability of, 578-579
substitute, 515 history of, 571
immunology of, 579
Calcium receptor, defects of, in hereditary indications for, 483
pancreatitis, 74 processing of, 576—577
procurement of, 572
Calcium signaling, disturbances of, in
pancreatitis, 2-4 retrieval of, 575-5
storage of, 577-578
Cam 5§.2, in renal cell carcinoma. 249 thawing of, 578
856 CUMULATIVE INDEX
Cardiovascular tissue grafts (continued ) Cholecystectomy, colorectal cancer after,
transport of, 576 147
types of, 572
Chromophobe renal cell carcinoma,
Cartilage grafts. See Soft tissue grafts. 321-324
eosinophilic variant, 321-324
Cathepsin B, in premature digestive
differential diagnosis of,
protease activation, in pancreatitis,
331-334
7-9
molecular diagnostic techniques
Causation, in malpractice, 779 for, 288-289
epidemiology of, 321
CD10,2 52in- 2r5e3n al cell carcinoma, 248-250, granular-appearing cells in, 322
gross pathology of, 321
CD14, in renal cell carcinoma, 252 immunohistochemical markers for,
252-255, 323
CD15, in renal cell carcinoma, 249-250, in Birt-Hogg-Dubé syndrome,
254-255 328-329
CD117, in renal cell carcinoma, 249, microscopic pathology of, 321-323,
251-254 436
molecular diagnostic techniques for,
CDKN gene mutations, in familial atypical 288-289, 323
multiple mole melanoma, 118—120 oncycotomas and, 326-328
polygonal type, 322
CDKN?2A gene mutations, in familial
prognosis for, 418, 439-440, 451-452
pancreatic cancer, 124
sarcomatoid differentiation or
Celecoxib, for colorectal cancer prevention, transformation of, 323, 441
159 versus Clear cell renal carcinoma with
eosinophilic cells, 334
Cellularity, in breast cancer, 734, 736
Chronic pancreatitis
Centers for Medicare and Medicaid
idiopathic. See Idiopathic chronic
Services, provisions to increase organ
pancreatitis.
donation, 608
in Kazal type pancreatic secretory
Ceramic materials, as bone graft substitutes, trypsin inhibitor mutation,
515 61-78
CFTR gene mutations Chymotrypsin, activation of, 62-63
idiopathic chronic pancreatitis in
Chymotrypsinogen, action of, 62-63
alcoholic pancreatitis and, 92-93
clinical features of, 87-88 CK7
gene testing in, 82-87, 90-92 in metanephric adenoma, 380
pancreatic secretory trypsin in renal cell carcinoma, 249, 253-255
inhibitor Kazal type and,
73-74 CK8, in renal cell carcinoma, 253,
pathobiology of, 88-90 311-312
prevention of, 96 CK 18, in clear cell renal cell carcinoma,
sclerosing cholangitis and, 93 311-312
susceptbility to, 95
trypsin inhibitor gene and, 82-87 CK19, in renal cell carcinoma, 253,
pancreatic carcinoma risk in, 122 311-312
pancreatic disease in, pathobiology of, CK 20, in renal cell carcinoma, 254-255
79-81
Claims, legal, review of, in breast fine
Chemotherapy needle aspiration biopsy, 782-783
for breast cancer, cytomorphologic
changes in, 692 Clear cell renal cell carcinoma, 305-316
for nephroblastoma, clinical features of, 305-306
gonadotoxicity of, 558-560 compact-alveolar pattern of, 308-309
cytology of, 310-311
Cholangitis, sclerosing, CFTR gene differential diagnosis of, 312
mutations in, 93 eosinophilic variant, 329-334
CUMULATIVE INDEX 857
epidemiology of, 305 genetics of, 137-143
familial, 260-265 histology of, 136-137
gross pathology of, 306-307 hyperplastic, 137, 153-154
immunohistochemical markers for, microsatellite instability testing
248-250, 253 of, 190-191
in Birt-Hogg-Dubé syndrome, pathology of, 153-154
269-270, 328-329 polypectomy for, 159
in tuberous sclerosis, 271-272 removal of, 159-162
microcystic pattern of, 309-310 screening for
microscopic pathology of, 307-310, in average risk, 150—154
434 in high risk, 154
molecular diagnostic techniques for, serrated, 137
281-283, 311-312 tubulous, 136
prognosis for, 418, 439-440, 451-452 tubulovillous, 136
sarcomatoid differentiation of, 441 villous, 136
tubular pattern of, 309 pseudopolyps of, 154
Clear cell sarcoma, renal, versus Colonoscopy, in colorectal cancer,
metanephric stromal tumor, 387 152-154, 163-164
Clostridial infections, transmission of, in Colorectal cancer, 135--177
bone grafts, 489 carcinoma in situ, 143
clinical presentation of, 145,
CLTC-TFE3 gene fusion, in renal
148-149
carcinoma, 364, 367
computed tomography in, 154-156
Collagenous spherulosis, of breast, epidemiology of, 135, 144-145
cytomorphology of, 694 genetic factors in, 137-145
hereditary nonpolyposis. See
Collecting duct carcinoma Hereditary nonpolyposis colon
immunohistochemical markers for, cancer.
251 histology of, 136-137, 143
low-grade (mucinous, tubular, and locations of, 143
spindle cell carcinoma), 393-398 magnetic resonance imaging in, 156
microscopic pathology of, 437-438 metastasis from, 144
molecular diagnostic techniques for, computed tomography in,
289-291 154-156
oncocytic features of, 330 magnetic resonance imaging in,
prognosis for, 419 156
versus tubulocystic carcinoma, microsatellite instability testing in,
399-400 184-185, 189-190
College of American Pathologists, tissue new developments in, 163-164
bank accreditation by, 495-496 pathology of, 143-144, 184-185
pathophysiology of, 136-143, 160
Colloid (mucinous) carcinoma, of breast, histologic, 136-137
736, 745, 789 molecular, 137-143
Colon prevention of, 158-162
cancer of. See Colorectal cancer. risk factors for, 144-145
obstruction of, in cancer, 149 screening for, 150—154
perforation of, in cancer, 149 in average risk, 150-154
polyps of in high risk, 154
cancer arising from, 136-145, underuse of, 135-136
154, 160 sporadic, microsatellite instability
clinical presentation of, 149-150 testing in, 184-185, 189-190
colonoscopy in, 152-154, spread of, testing for, 154-156
163-164 - staging of, 143-144, 154-158
differential diagnosis of, 153-154 stool genetic markers for,
DNA mismatch repair expression 162-163
in, 190-19] ultrasonography in, 156-158
endoscopic mucosal resection for, Comedocarcinoma, cytomorphology of,
161-162 724-726
858 CUMULATIVE INDEX
Communication, for malpractice Cystic fibrosis, pancreatic disease in,
prevention, 781—782 79-100
alcoholic pancreatitis and, 92-93
Compact-aiveolar pattern, of clear cell
carcinoma, 122
renal cell carcinoma, 308-309
genetic factors in, 90-92
Comparative genetic hybridization, for in cystic fibrosis carriers, 93-95
renal neoplasms, 280 pathobiology of, 79-81
chromophobe renal cell carcinoma, prevention of, 96
288 sclerosing cholangitis and, 93
oncocytoma, 288 susceptibility to, 95
Complex sclerosing lesion, of breast, Cystic nephroma, 354-355
cytomorphology of, 695
Cystic partially-differentiated
Computed tomography nephroblastoma, 354-355
in colorectal cancer, 154-156
Cytokeratin. See also CK.
in pancreatitis, 24-25
in renal cell carcinoma, 249, 251,
Conduct, malpractice and, 778 311-312
Conjunctival limbal cell transplantation, Cytokines. See also specific cytokines.
617-618 in acute pancreatitis, 28-29
in Helicobacter pylori infections, 201,
Connective tissue grafts. See Soft tissue
203
grafts.
Cytology. See also Cytomorphology.
Consent, for tissue donation, 476-477 in clear cell renal cell carcinoma,
Core needle biopsy, of breast, 635-637, 310-311
658-663, 679-688 Cytomegalovirus infections, from skin
Corneal grafts. See also Keratoplasty. grafts, 593-594
indications for, 483 Cytomorphology
C-reactive protein, in pancreatitis, of breast lesions
25-26, 31 benign, 689-712
common malignant, 733-760
Creatinine, in acute pancreatitis, 24 core needle biopsy in, 635-637,
Credentialing, for breast fine needle 658-663, 679-688
aspiration biopsy, 638-640 fine needle aspiration biopsy in.
See Breast lesions, fine
Creutzfeldt-Jakob disease, screening for, in needle aspiration biopsy in.
tissue donation, 477 in fibrocystic change, 713-731
Crohn’s colitis, colorectal cancer in, 147 in high-risk proliferative
disease, 713-731
Cryopreservation in premalignant disease,
of bone grafts, 512-513 713-731
of cardiovascular tissue, 577-578 medical-legal issues in, 777-785
of embryos, 560, 564-565 prognostic value of, 809-825,
of skin grafts, 600 827-843
of soft tissue grafts, 512-513 rare malignant, 761-775
of lumpectomy surgical margins,
Cullen sign, in pancreatitis, 23
intraoperative, 801-805
Cyclooxygenase-2 inhibitors, for colorectal of nipple fluid, 787-794
cancer prevention, 159 of sentinel lymph nodes,
intraoperative, 795-801
Cyclosporine, for skin graft rejection, 594
Cyst(s) D
breast, aspiration of, 670-672 Daclizumab, for islet cell transplantation,
pancreatic, molecular diagnosis of, 549-550
108-111
DCC gene, loss of
Cystic carcinoma, of breast, in colon cancer, 140, 142
cytomorphology of, 752 in gastric cancer, 209
CUMULATIVE INDEX 859
Death-associated protein-kinase, in gastric testing of, 478-479
cancer, 211-212 tissue retrieval from, 479-480
Denys-Drash syndrome, nephroblastoma DPC4 gene mutations, in familial pancreatic
in, 343-344 rancer, 124
Dermal matrix, acellular, for skin coverage, Duct ectasia, cytomorphology of, 690
592
Ductal carcinoma and ductal carcinoma in
Desmoid tumor (fibromatosis), of breast, situ, cytomorphology of, 724-727,
cytomorphology of, 702-703 735-738, 754-755
Diabetes mellitus Ductal lavage, for nipple fluid cytology,
colorectal cancer in, 147 791, 833-839
fibrocalculous pancreatic, 66
Ductoscopy, in breast lesions, 792,
in hereditary pancreatitis, 49-52
845-850
islet cell replacement for.
See Islet cell replacement Dukes classification, of colorectal cancer,
therapy. 143-144
Diet, colorectal cancer and, 146, 158 Duty, malpractice and, 779-780,
Dimethylsulfoxide, for cardiovascular tissue Dyshesion, in breast cancer, 734, 736
preservation, 577-578
DIRC2 gene mutations, in familial clear cell
renal cell carcinoma, 264
E
Discharge, nipple. See Nipple fluid E-cadherin
cytology. in Helicobacter pylori infections, 203
DNA in renal cell carcinoma, 249-251,
hypermethylation of, in gastric cancer, 253-254
210-212 Ecchymosis, in pancreatitis, 23
methylation of, in colon cancer, 143
Edwards syndrome (trisomy 18),
DNA mismatch repair deficiency nephroblastoma in, 343, 346
in colon polyps, 190-191
in gastrointestinal cancer ; Elastase
clinicopathologic behavior and, activation of, 62-63
186-187 polymorphonuclear, in acute
colon, 140-142 pancreatitis, 26-27, 31
for identification, 188-189 Electrocautery, in colon polypectomy,
gastric, 205-207
160
pathology and, 184-185
performance of, 183-184 Electron microscopy, in renal oncocytoma,
principles of, 179-181 319
test panels for, 181-183
Embryos, freezing of, 560, 564-565
DNA ploidy, in breast cancer, prognostic
Endoscopic mucosal resection, for
value of, 814-816
colorectal polyps and cancer,
Donors, tissue 161-162
bone, 508-509
Endoscopy, videocapsule, in colorectal
cardiovascular, 572-575
cancer, 164-165
consent forms for, 476-477
contraindications for donation, 478 Endotoxemia, in acute pancreatitis, 19
for autologous use, 480
Environmental factors, in colorectal cancer,
islet cells, 542-544
. 144, 146
living, tissue retrieval from, 480
reconstruction of body, 480 Eosinophilic variant
referral of, 476 of chromophobe renal cell carcinoma,
screening for risk factors in, 477-478 288-289, 321-324, 331-334
skin, 596-597 of clear cell renal cell carcinoma,
soft tissue, 508-509 329-334
860 CUMULATIVE INDEX
Epithelial membrane antigen Familial breast cancer, pancreatic
in metanephric adenoma, 380 carcinoma risk in, 121—122
in renal cell carcinoma, 249, 252-253,
Familial nephroblastoma, 345
323
Familial ovarian cancer, pancreatic
Epithelioid angiomyolipoma, renal, 331,
carcinoma risk in, 121—122
405-408
Familial pancreatic carcinoma. See
Estrogen receptors, in breast cancer,
Hereditary pancreatic carcinoma.
prognostic value of, 812-814
Familial renal cell carcinomas. 259-277
Ethical issues
clear cell, 260—265
in reproductive medicine, 565-566
in Birt-Hogg-Dubé syndrome,
in tissue donation, 477
269-270
Ethylene oxide sterilization in von Hippel-Lindau disease,
of bone grafts, 510-511 259-263
of soft tissue grafts, 510-511 leiomyomatosis with, 267-269
oncocytoma and, 270-271
Ewing renal tumor classification, 234
papillary, 265—267, 272
EWS-—FLI] gene fusion, in primitive tuberous sclerosis and, 271-272
neuroectodermal tumor, 408-410 with chromosome 3 translocation,
264
Expert review, in breast fine needle
aspiration biopsy, 783-784 Fascia grafts. See Soft tissue grafts.
Expert witness, in malpractice hearing, 779 Fat necrosis, in breast, cytomorphology
of, 691
Extracellular signal-regulated MAP kinases,
in Helicobacter pylori infections, 203 Fecal occult blood testing, in colonic
lesions, 150-151
Eye Bank Association of America,
607-609 Fertility, tissue banking for. See
accreditation by, 488, 490-491 Reproductive cell and tissue
standards of, 488, 490-491 banking.
Eye tissue grafts, 607-624 FH gene mutations, in hereditary
for keratoplasty, 610-616 leiomyomatosis with renal cell
corneal layers for, 610-611 © carcinoma, 267-269
lamellar, 611-614
FHIT gene mutations, in clear cell renal
penetrating, 614-616
cell carcinoma, 264, 282
for limbal stem cell transplantation,
616-620 Fiber, dietary, for colorectal cancer
conjunctival, 617-618 prevention, 158
ex vivo, 619-620
Fibroadenoma, of breast
keratolimbal, 618-619
cytology limitations in, 657-658
living-related, 618
cytomorphology of, 693, 700-701,
indications for, 483
754-755
legislation on, 608-609
regulations on, 609-610 Fibrocalculous pancreatic diabetes, 66
scleral, 620-621
Fibrocystic breast disease,
cytomorphology of, 713-714
F Fibromatosis, of breast, cywtomorphology
of, 702
Familial adenomatous polyposis
as cancer risk factor, 146 Fine needle aspiration biopsy
cancer prevention in, 158-159 in breast lesions. See Breast lesions,
differential diagnosis of, 153 fine needle aspiration biopsy in.
genetic factors in, 137-139 in clear cell renal cell carcinoma,
pancreatic carcinoma risk in, 122 310-311
Familial atypical multiple mole melanoma, FISH. See Fluorescent in situ
pancreatic carcinoma risk in, 118-120 hybridization (FISH).